Fundraising Fox
Seer
NASDAQ: SEERBoston, US · Founded 2017 · 153 employees on LinkedIn · 7 known investors
Find your way into Seer
Sign up to see every warm intro you have to Seer
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Seer team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Seer develops proteomics tools for large-scale protein analysis, including an assay, automation instrument, and analysis software for studying the proteome across human and non-human samples. Its products serve researchers running deep, reproducible proteomic studies at scale.
Founders & leadership
Seer was founded in 2017 by Omid Farokhzad.
Board
Investors · 7
How we know: open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Wing's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · reuters.com · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: board seat on SEC Form D · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$6M disclosed across 1 of 2 rounds · 2017–2019
▶$6MraisedJan 2018 · 11 investors · BiotechnologyRule 506(b)
- Philip MaExecutive Officer
- Terrance McGuireDirector
- Shadi AryanpourExecutive Officer
- David SingerDirector
- Omid FarokhzadDirector
- Robert LangerDirector
- Offering amount
- $6M
- Amount sold
- $6M
- Proceeds to insiders
- $425K
- First sale
- Dec 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Seer went on to found or lead other companies.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $2M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Seer do?
- Seer develops proteomics tools for large-scale protein analysis, including an assay, automation instrument, and analysis software for studying the proteome across human and non-human samples. Its products serve researchers running deep, reproducible proteomic studies at scale.
- Who founded Seer?
- Seer was founded by Omid Farokhzad in 2017.
- Who are Seer's investors?
- Seer's investors include SoftBank Vision Fund, Solasta Ventures, Wing, aMoon, Maverick Ventures, Polaris Partners, T. Rowe Price.
- How much funding has Seer raised?
- Seer has disclosed $6M raised across 1 of its 2 known rounds.
- Where is Seer headquartered?
- Seer is headquartered in Boston, US.